Mode
Text Size
Log in / Sign up
N/A N=54 Treatment

Digihaler in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Enrolled (actual)
54
Serious AEs
9.3%
Results posted
Jan 2024
Primary outcome: Primary: Mean Variability in Peak Inspiratory Flow (PIF) — 67.6 Liters/minute

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Albuterol eMDPI DS (Combination_product)
Age
Adult, Older Adult · 40+ yrs
Sex
All
Sponsor
University of North Carolina, Chapel Hill
Primary completion
Feb 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Mean Variability in Peak Inspiratory Flow (PIF)
67.6
PRIMARY
Variability in Peak Inspiratory Flow (PIF) as Measured by Coefficient of Variation
0.286
SECONDARY
Correlation of Self-Reported Inhaler Use With Actual Inhaler Use
-0.385
SECONDARY
Mean Variability in Inhalation Volume
1.395
SECONDARY
Variability in Inhalation Volume as Measured by Coefficient of Variation
0.426

Summary

This is a multi-center 3-month study to determine the variation in ProAir Digihaler metrics [peak inspiratory flow (PIF), inhalation volume, number of inhalation events] amongst COPD patients in the ambulatory setting.

Eligibility Criteria

Inclusion Criteria

  • Age >40 years old
  • History of cigarette smoking >=10 pack-years
  • Established COPD defined as physician diagnosis along with spirometry confirmation [post-bronchodilator (BD) forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC)<0.70] within the last two years and an FEV1 ≤80% predicted
  • Regular albuterol use (defined as at least one puff weekly for each of the last four weeks)
  • Currently non-hospitalized
  • Medical records confirmed history of two moderate AECOPD (defined as use of antibiotic or steroids to treat clinical event consistent with AECOPD) or one severe AECOPD (defined as emergency department/hospital visit) in prior 12 months
  • Access to smart phone, tablet or computer and internet
  • Willingness to switch current rescue inhaler/device to ProAir Digihaler

Exclusion Criteria

  • Allergy or inability/contraindication to use Albuterol Sulfate
  • Any condition that, in the opinion of the site investigator, would compromise the subject's ability to participate in the study
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05241288). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search